A moxifloxacin-based regimen for the treatment of recurrent drug-sensitive pulmonary tuberculosis: An open-label randomised controlled trial

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Rubeshan PerumalKogieleum Naidoo

Abstract

The substitution of moxifloxacin for ethambutol produced promising results for improved tuberculosis (TB) treatment outcomes. We conducted an open-label randomized trial to test whether a moxifloxacin-containing treatment regimen was superior to the standard regimen for the treatment of recurrent TB. The primary and secondary outcomes were sputum culture conversion rate at the end of 8 weeks and the proportion of participants with a favourable outcome, respectively. We enrolled 196 participants; 69.9% were male and 70.4% were co-infected with HIV. There was no significant difference between the study groups in the proportion of patients achieving culture conversion at the end of 8 weeks [83.0% (Moxifloxacin) vs 78.5% (Control), p=0.463], however the median time to culture conversion was significantly shorter (6.0 weeks, IQR 4.0 - 8.3) in the moxifloxacin group than the control group (7.9 weeks, IQR 4.0- 11.4) (p=0.018). A favourable end-of-treatment outcome was reported in 86 participants (87.8%) in the moxifloxacin group and 93 participants (94.9%) in the control group, for an adjusted absolute risk difference of -5.5 (95% CI -13.8 to 2.8, p=0.193) percentage points. There was a significantly higher proportion of participants ...Continue Reading

Associated Clinical Trials

Apr 15, 2014·Dr Nesri PadayatchiDr Nesri Padayatchi

References

May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yasmin Khaliq, George G Zhanel
Aug 15, 2003·American Journal of Respiratory and Critical Care Medicine·Roly D GoslingStephen H Gillespie
Oct 28, 2003·American Journal of Respiratory and Critical Care Medicine·Eric L NuermbergerJacques H Grosset
Aug 13, 2004·American Journal of Respiratory and Critical Care Medicine·Eric L NuermbergerJacques H Grosset
Oct 15, 2005·The Journal of Antimicrobial Chemotherapy·Stephen H GillespieTimothy D McHugh
Mar 3, 2006·The New England Journal of Medicine·Laura Y Park-WyllieMuhammad M Mamdani
May 6, 2006·American Journal of Respiratory and Critical Care Medicine·William J BurmanRichard E Chaisson
Aug 19, 2007·American Journal of Nephrology·Sijie ZhengDaniel W Coyne
Oct 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alma TostmannDick van Soolingen
May 2, 2009·American Journal of Respiratory and Critical Care Medicine·Susan E DormanUNKNOWN Tuberculosis Trials Consortium
Feb 26, 2010·The New England Journal of Medicine·Salim S Abdool KarimQuarraisha Abdool Karim
Oct 13, 2011·The Annals of Pharmacotherapy·Mohamed Fouad, Jason C Gallagher
Feb 13, 2013·Pediatric Pulmonology·Silvia GarazzinoPier-Angelo Tovo
Jun 8, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·Wing-Wai Yew, Eric Nuermberger
Jul 17, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Banurekha V VelayuthamJawahar M Shaheed
Sep 10, 2014·The New England Journal of Medicine·Stephen H GillespieUNKNOWN REMoxTB Consortium
Oct 23, 2014·The New England Journal of Medicine·Corinne S MerleUNKNOWN OFLOTUB/Gatifloxacin for Tuberculosis Project
Oct 23, 2014·The New England Journal of Medicine·Amina JindaniUNKNOWN RIFAQUIN Trial Team
Jan 20, 2017·The Lancet Infectious Diseases·Martin J BoereeUNKNOWN PanACEA consortium
Jul 26, 2017·Journal of Clinical Pharmacology·Anushka NaidooNesri Padayatchi
Aug 16, 2017·The Lancet Global Health· The Lancet Global Health
Jul 13, 2018·BMC Infectious Diseases·Conor D TweedStephen H Gillespie
Sep 22, 2018·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·D B CohenS B Squire

❮ Previous
Next ❯

Citations

Mar 21, 2019·The Cochrane Database of Systematic Reviews·Bhagteshwar SinghDerek J Sloan
May 7, 2020·Applied Microbiology and Biotechnology·Adetomiwa A AdenijiDu Toit Loots
Jul 14, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Isabelle R Weir, Sean Wasserman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.